Refine Search
(0)
(0)
(0)
(0)

Type 2 Diabetes - 'Me-too' Drugs

Despite the growing number of candidates in the T2D pipeline, KOLs interviewed by GlobalData have repeatedly communicated that pipeline ‘me-too’ T2D drugs fall short of meeting one of the most pressing unmet needs in the space: sustained glycemic control, with a focus on decreasing insulin resistance and preserving β-cell function. As such, KOLs have largely shifted their sights from the ‘me-too’ populated late-stage pipeline to the early-stage pipeline in the hopes that novel treatments will help address the aforementioned unmet need.

PharmaPoint: Type 1 Diabetes – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • March 2015
Add to Basket Quick View Add to Saved List

Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at ...